Skip to main content
main-content
Erschienen in: Endocrine 3/2022

08.09.2022 | Original Article

Incomplete response to therapy in intermediate- and high-risk thyroid cancer

verfasst von: Ali S. Alzahrani, Noha Mukhtar

Erschienen in: Endocrine | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Context

The American Thyroid Association (ATA) risk stratification system predicts risk of recurrence of differentiated thyroid cancer (DTC). Although the majority of patients achieve an excellent response, patients with intermediate- or high-risk DTC are at a significant risk of developing incomplete responses. We undertook this work to understand the factors associated with development of biochemically or structurally incomplete response in these two risk subgroups of DTC.

Patients and methods

We retrospectively reviewed 287 consecutive patients with intermediate- (213 patients) or high-risk (74 patients) DTC. All patients underwent total thyroidectomy with (223 patients) or without (64 patients) lymph node dissection and 94% of them received at least one dose of I-131ablation/therapy. Univariate and multivariate analysis and Kaplan Meier analysis were used to compare patients who achieved an excellent response with those who continued to have biochemically or structurally incomplete responses.

Results

In univariate and multivariate analyses, age (P 0.002, Odds ratio 4.8, 95% CI: 1.8–12.9), tumor size (P 0.027, Odds ratio 1.30, 95% CI: 1.03–1.64) and distant metastases (P < 0.0001, Odds ratio 44.6, 95% CI: 10.7–184.5) were significantly associated with the risk of developing biochemically or structurally incomplete statuses. Patients ≥ 55 years, tumors > 2.5 cm and presence of distant metastasis were associated with higher risk of incomplete response and death from DTC. However, when this analysis was performed on intermediate and high-risk groups separately, only age was consistently associated with risk of biochemically or structurally incomplete response in either and both groups.

Conclusion

Age is a strong predictor of biochemically and structurally incomplete responses in patients with intermediate and high-risk DTC.
Literatur
1.
Zurück zum Zitat B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. Off. J. Am. Thyroid. Assoc. 26(1), 1–133 (2016). https://​doi.​org/​10.​1089/​thy.​2015.​0020 CrossRef B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. Off. J. Am. Thyroid. Assoc. 26(1), 1–133 (2016). https://​doi.​org/​10.​1089/​thy.​2015.​0020 CrossRef
7.
Zurück zum Zitat R.M. Tuttle, H. Tala, J. Shah, R. Leboeuf, R. Ghossein, M. Gonen et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid.: Off. J. Am. Thyroid. Assoc. 20(12), 1341–1349 (2010). https://​doi.​org/​10.​1089/​thy.​2010.​0178 CrossRef R.M. Tuttle, H. Tala, J. Shah, R. Leboeuf, R. Ghossein, M. Gonen et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid.: Off. J. Am. Thyroid. Assoc. 20(12), 1341–1349 (2010). https://​doi.​org/​10.​1089/​thy.​2010.​0178 CrossRef
8.
Zurück zum Zitat F. Pitoia, F. Bueno, C. Urciuoli, E. Abelleira, G. Cross, R.M. Tuttle, Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. Thyroid.: Off. J. Am. Thyroid. Assoc. 23(11), 1401–1407 (2013). https://​doi.​org/​10.​1089/​thy.​2013.​0011 CrossRef F. Pitoia, F. Bueno, C. Urciuoli, E. Abelleira, G. Cross, R.M. Tuttle, Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. Thyroid.: Off. J. Am. Thyroid. Assoc. 23(11), 1401–1407 (2013). https://​doi.​org/​10.​1089/​thy.​2013.​0011 CrossRef
11.
Zurück zum Zitat R. Tuttle, L. Morris, B. Haugen, M. Amin, S. Edge, F. Greene. AJCC cancer staging manual. ed. 2017; 8:1–19. R. Tuttle, L. Morris, B. Haugen, M. Amin, S. Edge, F. Greene. AJCC cancer staging manual. ed. 2017; 8:1–19.
12.
Zurück zum Zitat S.A. Ghaznavi, I. Ganly, A.R. Shaha, C. English, J. Wills, R.M. Tuttle, Using the American thyroid association risk-stratification system to refine and individualize the american joint committee on cancer eighth edition disease-specific survival estimates in differentiated thyroid cancer. Thyroid.: Off. J. Am. Thyroid. Assoc. 28(10), 1293–1300 (2018). https://​doi.​org/​10.​1089/​thy.​2018.​0186 CrossRef S.A. Ghaznavi, I. Ganly, A.R. Shaha, C. English, J. Wills, R.M. Tuttle, Using the American thyroid association risk-stratification system to refine and individualize the american joint committee on cancer eighth edition disease-specific survival estimates in differentiated thyroid cancer. Thyroid.: Off. J. Am. Thyroid. Assoc. 28(10), 1293–1300 (2018). https://​doi.​org/​10.​1089/​thy.​2018.​0186 CrossRef
23.
Zurück zum Zitat P. Trimboli, A. Piccardo, A. Signore, S. Valabrega, A. Barnabei, G. Santolamazza et al. Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American thyroid association stratification system. Thyroid.: Off. J. Am. Thyroid. Assoc. 30(5), 713–719 (2020). https://​doi.​org/​10.​1089/​thy.​2019.​0688 CrossRef P. Trimboli, A. Piccardo, A. Signore, S. Valabrega, A. Barnabei, G. Santolamazza et al. Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American thyroid association stratification system. Thyroid.: Off. J. Am. Thyroid. Assoc. 30(5), 713–719 (2020). https://​doi.​org/​10.​1089/​thy.​2019.​0688 CrossRef
26.
Zurück zum Zitat M.G. Castagna, F. Maino, C. Cipri, V. Belardini, A. Theodoropoulou, G. Cevenini et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur. J. Endocrinol. 165(3), 441–446 (2011). https://​doi.​org/​10.​1530/​eje-11-0466 CrossRefPubMed M.G. Castagna, F. Maino, C. Cipri, V. Belardini, A. Theodoropoulou, G. Cevenini et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur. J. Endocrinol. 165(3), 441–446 (2011). https://​doi.​org/​10.​1530/​eje-11-0466 CrossRefPubMed
28.
Zurück zum Zitat S.W. Jang, J.H. Park, H.J. Kwon, J.H. Yoon. Optimal cutoff values of primary tumour size to better predict long-term outcomes in patients with papillary thyroid carcinoma undergoing total thyroidectomy: A preliminary study using restricted cubic spline analysis. Clin Endocrinol (Oxf). 2021. https://​doi.​org/​10.​1111/​cen.​14657 S.W. Jang, J.H. Park, H.J. Kwon, J.H. Yoon. Optimal cutoff values of primary tumour size to better predict long-term outcomes in patients with papillary thyroid carcinoma undergoing total thyroidectomy: A preliminary study using restricted cubic spline analysis. Clin Endocrinol (Oxf). 2021. https://​doi.​org/​10.​1111/​cen.​14657
34.
Zurück zum Zitat J. Mihailovic, L. Stefanovic, M. Malesevic, Differentiated thyroid carcinoma with distant metastases: probability of survival and its predicting factors. Cancer Biotherapy Radiopharmaceuticals 22(2), 250–255 (2007) CrossRefPubMed J. Mihailovic, L. Stefanovic, M. Malesevic, Differentiated thyroid carcinoma with distant metastases: probability of survival and its predicting factors. Cancer Biotherapy Radiopharmaceuticals 22(2), 250–255 (2007) CrossRefPubMed
35.
Zurück zum Zitat C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J. Travagli et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91(8), 2892–2899 (2006) CrossRefPubMed C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J. Travagli et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91(8), 2892–2899 (2006) CrossRefPubMed
Metadaten
Titel
Incomplete response to therapy in intermediate- and high-risk thyroid cancer
verfasst von
Ali S. Alzahrani
Noha Mukhtar
Publikationsdatum
08.09.2022
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03187-5

Weitere Artikel der Ausgabe 3/2022

Endocrine 3/2022 Zur Ausgabe

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.